Abbott GMP Warning Letter Accelerates Monitoring Systems Validation Work
This article was originally published in The Gray Sheet
Executive Summary
Abbott is accelerating enhancements to its monitoring systems validation program at the company's Austin, Texas facility following receipt of an FDA warning letter related to production of hospital products, including I.V. drug solutions
You may also be interested in...
Hospira Assumes Responsibility For Recent Abbott Warning Letter
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets
Hospira Assumes Responsibility For Recent Abbott Warning Letter
Abbott spin-off Hospira will be accountable for resolving FDA quality oversight and manufacturing concerns related to the firm's intravenous administration sets
Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
Costs related to Abbott's FDA consent decree could approach $1 bil. in lost revenue alone following a failed follow-up inspection of the company's Lake County, Illinois diagnostic manufacturing operations